Application of niclosamide ethanolamine salt in preparation of medicine for treating systemic lupus erythematosus and complications thereof

A technology of niclosamide ethanolamine salt and lupus erythematosus, which is applied in the directions of digestive system, drug combination, urinary system diseases, etc., can solve the problems of difficult treatment, lingering and difficult to heal, complex etiology of lupus nephritis, etc.

Active Publication Date: 2020-04-17
SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Systemic lupus erythematosus can cause skin damage, lupus nephritis, immune system dysfunction, lymphadenopathy, splenomegaly, blood system damage, serositis, nervous system damage and many other complications; among them, lupus nephritis is a secondary The common cause of glomerulonephritis, the cause of lupus nephritis is complicated, the treatment is difficult, and the condition is lingering and difficult to heal. Proteinuria, progressive increase of serum creatinine, glomerulosclerosis and renal tubular damage are its main clinical features in the early stage; currently , there is no clinically effective drug for delaying the progression of kidney disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of niclosamide ethanolamine salt in preparation of medicine for treating systemic lupus erythematosus and complications thereof
  • Application of niclosamide ethanolamine salt in preparation of medicine for treating systemic lupus erythematosus and complications thereof
  • Application of niclosamide ethanolamine salt in preparation of medicine for treating systemic lupus erythematosus and complications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] Embodiments of the present invention will be described in detail below in conjunction with specific examples, but those skilled in the art will understand that the following examples are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Those who do not indicate specific conditions in the embodiments, carry out according to conventional conditions. The reagents or instruments used were not indicated by the manufacturer, and they were all conventional products that could be purchased from the market.

[0034] The embodiment of the present invention has carried out following research:

[0035] 1. To study the effect of NEN on serum anti-ds-DNA antibody of MRL / lpr lupus mice;

[0036] 2. To study the effect of NEN on the 24h urine protein excretion rate of MRL / lpr lupus mice;

[0037] 3. Study the effect of NEN on serum creatinine in MRL / lpr lupus mice;

[0038] 4. Study the effect of NEN on serum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of niclosamide ethanolamine salt in preparation of a medicine for treating systemic lupus erythematosus and complications thereof. The niclosamide ethanolaminesalt (NEN) can reduce the serum anti-ds-DNA antibody level, reduce the MRL / lpr mouse proteinuria excretion, reduce the serum creatinine and serum urea nitrogen level, improve glomerulosclerosis and renal tubule interstitial injury, relieve the spleen swelling, relieve lymph node hyperplasia swelling and relieve the skin injury.

Description

technical field [0001] The application relates to the technical field of medicines, in particular to the application of niclosamide ethanolamine salt in the preparation of medicines for treating systemic lupus erythematosus and its complications. Background technique [0002] Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a slow onset and insidious onset, various and varied clinical manifestations, and an autoimmune disease involving many systems and organs. and humoral immune dysfunction, produce a variety of autoantibodies, which can affect the skin, serosa, joints, kidneys and central nervous system, etc., and are characterized by autoimmunity. There are a variety of autoantibodies in patients, which not only affect humoral immunity Cellular immunity and complement system also changed. The pathogenesis is mainly due to the formation of immune complexes, the exact cause is unknown, and the condition is an alternating process of repeated attacks and remis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/167A61P37/02A61P13/12A61P43/00A61P1/00A61P17/00
CPCA61K31/167A61P37/02A61P13/12A61P43/00A61P1/00A61P17/00
Inventor 韩鹏勋孙惠力邵牧民余学问翁文慈
Owner SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap